On September 8, 2026, Veru Inc. announced it will advance its oral drug candidate sabizabulin into a planned Phase 2b clinical trial for metastatic pancreatic cancer resistant to daraxonrasib (RASONQUE). This strategic pivot follows positive preclinical data showing sabizabulin's potent anticancer activity in daraxonrasib-resistant KRAS-driven cell lines. Consequently, the company will cease development of sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease. Veru plans to seek regulatory clarity via an FDA pre-IND meeting in Q4 2026. Additionally, the Phase 2b PLATEAU trial for enobosarm is fully enrolled with interim analysis expected in Q1 2027. Veru Inc. operates as a late-stage biopharmaceutical company focused on developing innovative medicines for cardiometabolic and oncology indications.

Veru Inc. reported fiscal third quarter results ending June 30, 2026, with a net loss of $7.0 million ($0.30 per share), compared to a $7.3 million loss in the prior year period. Research and development expenses rose to $4.4 million from $3.0 million, while general and administrative costs fell to $3.4 million from $5.0 million. The company holds $23.9 million in cash as of June 30, 2026. Clinically, the Phase 2b PLATEAU trial for enobosarm combined with semaglutide fully enrolled 239 patients, exceeding its target of 200. Veru secured a clinical supply agreement with Novo Nordisk and received a USPTO notice of allowance for a key patent covering the combination therapy, extending protection until at least October 2044. Interim analysis results are expected in Q1 2027. Veru Inc. is a late-stage biopharmaceutical company developing treatments for cardiometabolic and inflammatory diseases.

Veru Inc. entered into a clinical supply agreement with Novo Nordisk A/S to support its Phase 2b PLATEAU clinical study evaluating the combination of enobosarm and Wegovy in older adults with obesity. Under the terms, Novo Nordisk will provide Wegovy at no charge for the study, while Veru grants Novo Nordisk a right of first negotiation for future combination development of enobosarm with Novo Nordisk GLP-1 products.